333 results about "Gouty arthritis" patented technology

The invention provides a flurbiprofen hydrogel plaster and a composition thereof. In the composition, the content of flurbiprofen is 0.1-3wt%, and a hydrogel substrate accounts for the rest. Based on the total weight of the hydrogel substrate, the hydrogel substrate comprises the following components: 0.1-40wt% of a hydrophilic base material, 0.01-2wt% of a crosslinking agent, 0.01-4wt% of a crosslinking regulator, 10-60wt% of a humectant, 0.05-45wt% of a penetration enhancer and 10-85wt% of a solvent. According to the flurbiprofen hydrogel plaster provided by the invention, a small number of medicines are used, and the permeability and stability are good; and the flurbiprofen hydrogel plaster can be applied to various arthralgia diseases such as rheumatic arthritis, gouty arthritis, ankylosing spondylitis, tenosynovitis, muscle pain and lumbago.

The invention relates to a pain-relieving mixture for the treatment of gouty arthritis, which pertains to the field of pharmaceutical formulations, the technology is characterized in that: the parts by weight of the raw materials are: 6 to 10 percent amur corktree bark, 12 to 16 percent sevenlobed yam rhizome, 4 to 6 percent rhubarb, 8 to 12 percent Japanese honeysuckle stem, 6 to 9 percent Indian iphigenia bulb, 12 to 16 percent spreading hedyotis herb, 6 to 10 percent glabrous greenbrier rhizome, 4 to 6 percent frankincense, 4 to 6 percent myrrh, 6 to 10 percent clematis root, 6 to 10 percent largeleaf gentian root and 6 to 9 percent earthworm, and the sum of the percentages of the components of the raw materials is equal to 100 percent. The invention can effectively alleviate the symptoms of gouty arthritis, prevent and treat the repeated attacks of gouty arthritis, lower blood uric acid, have no toxicity or side effects and have definite efficacy.

The present invention relates to novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel hetereocycles of the general formula (I). Also included is a method of treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection in a mammal comprising administering an effective amount of a compound of formula (I) as described above.

The present invention relates to compounds having the general formula

or a pharmaceutically acceptable salt thereof, wherein R¹ is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R¹ is additionally substituted; and R² is a substituted C_1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

The invention relates to application of a stilbene derivative and pharmaceutically acceptable salts thereof to preparation of medicines or health-care products for preventing and/or treating hyperuricemia, and acute gout, chronic gout, gouty arthritis, gout attack, uric acid nephrolithiasis and gouty nephropathy caused by the hyperuricemia. The stilbene derivative is used as an active component for preparing the medicines for treating the hyperuricemia, can reduce the concentration of uric acid in blood, has a significant effect on treatment of the hyperuricemia, does not have toxic or side effects and has good safety.

The invention belongs to the field of traditional Chinese medicines, relates to traditional Chinese medicines and health care preparations, and especially relates to a medicinal food formula and a medicinal edible preparation for preventing and treating hyperuricemia and gout. The medicinal edible preparation comprises traditional Chinese medicines or active ingredients of 10 to 80 parts of plantain seed and 10 to 80 parts of semen cuscutae. The medicinal edible preparation is prepared from extract of plantain seed and semen cuscutae, and auxiliary materials, and can be processed into tablets, pills, electuary, an oral liquid, a tea bag and a health-care food additive. An animal acute toxicity test and a sub-chronic toxicity test prove that the medicinal edible preparation is safe and has no toxic or side effect. A pharmacodynamic animal test proves that the medicinal edible preparation can obviously reduce blood uric acid and improve kidney uric acid crystallization and injuries. The medicinal edible preparation as a treatment drug or a health-care product can be used for patients suffering from hyperuricemia and gout, can obviously reduce a blood uric acid level and relieve gouty arthritis symptoms, and has good safety.

The invention relates to a Chinese medicinal composition for reducing blood uric acid. The Chinese medicinal composition consists of active ingredient extracts prepared from glabrous greenbrier rhizome and oriental water plantain rhizome serving as raw materials and medicinal dressing, and can be prepared into various medicinally acceptable preparations and injection. The Chinese medicinal composition has the effects of removing dampness, releasing toxin and benefiting joints, and is mainly used for gouty arthritis and hyperuricemia.

The invention discloses a traditional Chinese medicine for treating gout. The traditional Chinese medicine is prepared from the following raw materials according to a weight ratio: 10-20 of pueraria, 20-40 of gynostemma, 10-20 of ligustrum lucidum, 30-50 of cordyceps, 15-25 of cinnamon, 30-50 of papaya, 10-20 of angelica, 15-25 of anemarrhena, 5-15 of safflower, 20-40 of white peony root, 3-10 ofplantago, 5-10 of radix semiaquilegiae, 15-25 of desmodium, 10-20 of gardenia, 5-10 of orienavine, 5-15 of radix isatidis, 10-20 of silkworm excrement, 5-10 of trachelospermum jasminoides, 5-18 of caulis spatholobi, 10-20 of salvia miltiorrhiza, 5-15 of prepared rehmannia root, 10-20 of clematis chinensis and 10-20 of trogopterus dung. The traditional Chinese medicine for treating gout disclosed by the invention contains carefully selected traditional Chinese medicines which are matched scientifically, has the effects of promoting blood circulating and removing obstruction in channels, expelling wind and removing dampness, eliminating swelling and alleviating paint, clearing away heat and toxic materials, warming channels and eliminating stasis and the like, and has better treatment effect on acute and chronic gout as well as gouty arthritis.

The invention discloses a paederia scandens extract. The extract contains iridoid glycoside compounds, and is characterized in that the iridoid glycoside compounds are mainly composed of 20.0-50.0% of paederosidic acid, 2.0-25.0% of paederoside and 1.0-10.0% of paederosidic acid methyl ester. The paederia scandens extract is prepared by the following ways: a) extracting paederia scandens medicinal material by virtue of ethanol to obtain an extracting solution; b) concentrating the extracting solution until no alcohol smell exists, carrying out macro-porous adsorption resin chromatography, eluting with water and 80-90% of ethanol sequentially, collecting eluate, and drying the eluate under reduced pressure to obtain the paederia scandens extract. The paederia scandens extract disclosed by the invention is applicable to the preparation of medicines which are capable of reducing uric acid, and also resisting inflammation and gouty arthritis.

The invention relates to a drug for treating purine metabolic disorder disease, provides a flavonoids compound represented by the formula (I) and a modified derivative thereof, and a use in inhibition of xanthine oxidase activity and promotion of uric acid excretion function, wherein R1, R2 and R3 independently represent -H or monosaccharide residues, and R4 represents -H or -OH. In particular, the drug is used for treating purine metabolic disorder disease, and can be used for treating hyperuricemia and related diseases and reducing a individual serum UA level; the drug is used for treating hyperuricemia; the drug is used for treating the related diseases, such as for treating gouty arthritis and arthrophlogosis caused by hyperuricemia, and for treating chronic interstitial nephritis, kidney stones and the like caused by hyperuricemia. The drug has the advantages of natural chemical structure, safety, low toxicity, rapid curative effect and fewer side effects. (I).

The invention discloses a medicine for treating gouty arthritis and hyperuricemia. The medicine is prepared by the following bulk drugs by weight percentage: 10 to 60 parts of gypsum, 5 to 20 parts of anemarrhena, 10 to 40 parts of Japanese honeysuckle stem, 10 to 40 parts of plantago, 15 to 40 parts of Smilax glabra, 5 to 20 parts of radix paeoniae rubrathe, 3 to 15 parts of licorice, 1 to 15 parts of scorpion and 5 to 60 parts of coix seeds. The medicine provided in the invention has obvious therapeutical effects on gouty arthritis and hyperuricemia and no toxic and side effects, and is safe and effective. The invention also discloses the preparation method for granules of the medicine, and the granules have the characteristics of convenient administration, good mouthfeel and rapid effect.

The invention discloses novel medicinal application of coreopsis tinctoria, and particularly relates to application of coreopsis tinctoria extract to preparing medicines for treating hyperuricemia. The novel medicinal application has the advantages that effects of treating the hyperuricemia can be realized by the coreopsis tinctoria extract, the concentration of uric acid in blood can be effectively reduced, and excellent curative effects can be realized for metabolic diseases such as acute gout, chronic gout, gouty arthritis, gout flare, uric acid renal lithiasis and gouty nephropathy which are relevant to the hyperuricemia.

The invention discloses a medicinal composition for treating rheumatism. The medicinal composition is prepared from the following Chinese medicinal herbs serving as raw materials in parts by weight: 3-18 parts of wild ginger, 3-24 parts of dahurian angelica root, 3-18 parts of Chinese angelica, 6-36 parts of safflower, 3-18 parts of astragalus, 3-18 parts of barbary wolfberry fruit, 6-36 parts of honeysuckle flower, 3-18 parts of white paeony root, 3-18 parts of kudzuvine root, 2-8 parts of dried ginger and the like. The medicinal composition has good curative effects on various rheumatisms such as migratory arthralgia, arthritis, arthritis, obstinate arlhralgia and like, and has good curative effects on other similar relevant rheumatisms such as knee osteoarthritis, lumbar vertebra hyperosteogeny, knee osteoarthritis, gouty arthritis, ischemic necrosis of femoral head, women rheumatism (general aching during menstruation, pantalgia after childbirth and puerperal arthralgia), lupus sebaceous, psoriasis, sicca syndrome, and the like.

The invention discloses a traditional Chinese medicine composition for treating gouty arthritis. According to the traditional Chinese medicine, gouty arthritis belongs to the domain of 'arthralgia syndrome'. The disease is caused by endoretention of damp heat, detained skeleton, poor qi-blood circulation, stagnation leading to pain caused by overfeeding of greasy and surfeit flavor usually, resulting vital energy and blood retained at the local part of the scleromere, glow and swelling. Thus, the traditional Chinese medicines, namely euphorbia thymifolia, tuckahoe, yam rhizome, tonkin pepper herb, tree falsespiraea bark, siphon, delavay violet root, featherycleft horsegentian root, caulis lonicerae, herba ajugae, honeysuckle stem, herba ajugae, and rhizoma curculiginis are selected, and prepared into soup by a manufacturing laboratory in a hospital. The clinical test shows that the total effective rate achieves 96.9%; the blood uric acid is obviously reduced; the traditional Chinese medicine composition is worthy of clinical application.

The invention discloses a medicament for treating gouty arthritis and a preparation method thereof. The medicament is mainly prepared from rhizoma atractylodis, golden cypress, semen coicis, pyrrosia lingua, radix achyranthis bidentatae, moutan bark and honeysuckle. The medicament disclosed by the invention has the effects of nourishing liver and kidney, strengthening muscles and bones, eliminating wind-damp and clearing the channels and collaterals; the medicament is quick in taking effect in treating gouty arthritis and short in course of treatment without recurrence.

The present invention relates to the technical field of medicine, specifically to an application of salvianolic acid C in preparation of drugs for prevention and treatment of hyperuricemia. The results of the pharmacological test show that: the salvianolic acid C can be adopted as a xanthine oxidase (XO) inhibitor to prevent and treat hyperuricemia and complications of the hyperuricemia, wherein the complications caused by the hyperuricemia comprise: gout, gouty arthritis, gouty nephropathy, lithangiuria, cardiovascular diseases and other diseases.

The present invention relates to compounds having the general formula

or a pharmaceutically acceptable salt thereof. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

The invention discloses a compound oral Chinese patent medicament for treating gout, which consists of the following raw materials in percentage by weight based on crude medicaments: 5 to 20 percent of phellodendron, 5 to 20 percent of root of common peony, 5 to 30 percent of sevenlobed yam rhizome, 5 to 30 percent of desmodium, 3 to 10 percent of mastic, 3 to 10 percent of myrrh, 5 to 25 percent of suberect spatholobus stem, 5 to 20 percent of rhizoma atractylodis, 5 to 28 percent of oriental waterplantain rhizome, 5 to 20 percent of medicinal cyathula root, and 5 to 20 percent of root of largeleaf gentian. The invention discloses a preparation method for the medicament, and the formulations of the medicament are tablets, capsules, granules, oral liquid, dropping pills, and other common formulations. The compound oral Chinese patent medicament is used for treating acute and chronic gout, gouty arthritis, gouty stone, and gouty nephrotic syndrome, is a new medicament with obvious curative effects and safe administration for clinical treatment, and has significant application value.

The invention provides a medicine composition for preventing and treating arthritis. The medicine composition comprises the following components in percentage by weight: 15%-35% of glucosamine hydrochloride, 20%-40% of biological calcium carbonate, 5%-20% of rhizoma drynariae extract, 1%-5% of casein phosphopeptides, 10%-20% of chondroitin sulfate and 10%-30% of epimedium extract. The medicine composition has the advantages of being capable of obviously inhibiting inflammatory cell factors in serum and joint fluid of arthritics patients, relieving the symptoms and signs of the patients, adjusting the immunologic functions of the patients, and effectively preventing and treating diseases such as rheumatism, rheumatoid arthritis, osteoarthritis and gouty arthritis. The invention also provides an application of the medicine composition in the preparation of medicines for preventing and treating diseases such as the rheumatism, the rheumatoid arthritis, the osteoarthritis and the gouty arthritis.

The present invention relates to compounds having the general formula

or a pharmaceutically acceptable salt thereof, wherein R¹ is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, 0 and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R¹ is additionally substituted; and R² is a substituted C_1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

The invention is a medicine for curing arthrolithiasis and the preparing method thereof, characterized by that it is prepared of White Paeony Root, Fenbixian, Mulberry Twig, Herba Siegesbeckiae, Coix Seed, Glabrous Greenbrier Rhizome, Medicinal Cyathula Root, Clematis Root, and Membranous Milkvetch Root in certain proportion and able to be made into any oral form. It has functions of clearing heat and discharging corruption, tonifying spleen and promoting diuresis, and dispelling the wind and removing rheumatism and is used for curing diseases caused by damp, heat, accumulation and mass, especially pains in limbs, muscles and veins, red and swelling, fever and pains of joint, and inconvenient bending and extending. The curative effect study verifies that it can reduce the uric acid content of the blood serum of an animal with high- uric acid content blood disease, improve rheological indexes of the blood, and treat gouty arthritis and common inflammation and has good pain-stopping function and very curative effect on acute and chronic grouts, where the clinical effective rate is up to 91.36%.